Onconetix (Onconetix) Debt-to-Equity : -0.72 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Onconetix Debt-to-Equity?

Onconetix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.24 Mil. Onconetix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.16 Mil. Onconetix's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-21.53 Mil. Onconetix's debt to equity for the quarter that ended in Mar. 2024 was -0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Onconetix's Debt-to-Equity or its related term are showing as below:

ONCO' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.77 Med: 0.15 Max: 1.26
Current: -0.72

During the past 5 years, the highest Debt-to-Equity Ratio of Onconetix was 1.26. The lowest was -1.77. And the median was 0.15.

ONCO's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs ONCO: -0.72

Onconetix Debt-to-Equity Historical Data

The historical data trend for Onconetix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Onconetix Debt-to-Equity Chart

Onconetix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.77

Onconetix Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial											-	1.01	1.26	-1.77	-0.72

Competitive Comparison of Onconetix's Debt-to-Equity

For the Biotechnology subindustry, Onconetix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onconetix's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Onconetix's Debt-to-Equity falls into.

Onconetix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Onconetix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.693	+	0.193)	/	-5.602
	=	-1.76

Onconetix's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.244	+	0.158)	/	-21.533
	=	-0.72

Onconetix (NAS:ONCO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Onconetix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Onconetix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Onconetix (Onconetix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Onconetix Inc (NAS:ONCO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

J4T:Germany

Address

201 East Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202

Website

https://www.onconetix.com

Onconetix Inc is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has a product named Entadfi an FDA approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Executives

Neil J Campbell	director, officer: Chief Executive Officer	225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458
Bruce Harmon	officer: Chief Financial Officer	316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990
Timothy R. Ramdeen	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Vuk Jeremic	director	BLUE WATER VACCINES INC., 201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
Cincinnati Cornerstone Investors Bwv I, Llc	10 percent owner	2900 READING ROAD, SUITE 410, CINCINNATI OH 45206
Cincinnati Cornerstone Capital Llc	other: Manager-Cinti Cornerstone Inv.	2900 READING RD, SUITE 410, CINCINNATI OH 45206
Joseph Hernandez	10 percent owner, officer: CEO	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Simon Tarsh	director	201 E. FIFTH STREET SUITE 1900, CINCINNATI OH 45202
Allan Shaw	director	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Erin Henderson	officer: Chief Business Officer	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Jon Garfield	officer: CFO	11111 SANTA MONICA BLVD., SUITE 650, LOS ANGELES CA 90025
Michael Venerable	director	201 E. FIFTH STREET, SUITE 1900, CINCINNATI OH 45202